Chloe Chepigin

Chloe Chepigin supports clients with research and analysis spanning a variety of healthcare sectors and stakeholders.

She applies her background in drug pricing legislation, vaccine development, and health economics to advise a range of clients on diverse healthcare policy issues.

Prior to joining Avalere, Chloe supported the development of the World Health Organization’s National Assessment Tool for the Sustainable Local Production of Influenza Vaccines and produced the final progress report for the Global Action Plan for Influenza Vaccines. Additionally, she worked with the Office of Connecticut State Representative Sean Scanlon, where she collaborated with state legislators to develop bills concerning drug pricing transparency, access to essential health benefits, and value-based insurance design.

Chloe has an MPH from Yale School of Public Health and a BA in public health and international relations from the University of Rochester.

Authored Content

Nearly 80,000 people died during the 2017–2018 influenza season. Only 37% of adults were vaccinated. Several novel emerging products could make vaccination more accessible and effective, potentially reshaping the market and lowering influenza disease burden.